, drug-drug interactions, and adverse events Abbreviations: CK: creatine kinase; CV: cardiovascular; CVD: cardiovascular disease; dL: deciliter; gm: grams; LFT: liver function test; mg: milligrams; PCSK9: proprotein convertase subtilisin/kexin type 9; RCT: randomized controlled trial; TG: triglyceride; ULN: upper limit of the normal range Guideline Work Group Organization Name* Department of Veterans Affairs John R. Rick Downs, MD, FACP (Champion) Jennifer Ballard-Hernandez, DNP, FNP-BC Andrew Buelt, DO Mark Donahue, MD Cathy Kelley, PharmD Amanda Logan, MPS, RDN, LD Sundar Natarajan, MD, MSc Lance Spacek, MD Department of Defense Lt Col Brian Neubauer, MD, MHPE, FACP (Champion) COL Patrick G. O Malley, MD, MPH, FACP (Champion) CDR Michael J. Arnold, MD Karen Grace, PharmD Joan Ritter, MD, FACP LTC Nikki Smith, DNP, FNP-BC Lauren Thomas, MS, RD, LD Elena Vagichev, PharmD, BCPS, BCACP VA/DoD CPG for the Management of Dyslipidemia for Cardiovascular Risk Reduction Provider Summary Organization Name* Office of Quality and Patient Safety Veterans Health Administration M. Eric Rodgers, PhD, FNP-BC James Sall, PhD, FNP-BC Rene Sutton, BS, HCA Office of Evidence Based Practice U.S. Army Medical Command Corinne K. B. Devlin, MSN, RN, FNP-BC Lisa Jones, BSN, RN, MHA, CPHQ The Lewin Group Clifford Goodman, PhD Christine Jones, MS, MPH, PMP Erika Beam, MS Ben Agatston, JD, MPH Nicolas Stettler-Davis, MD, MSCE Ruben Ganesh, BS ECRI James Reston, PhD, MPH Jeff Oristaglio, PhD Joann Fontanarosa, PhD Kristy McShea, MSLIS Benjamin Rouse, MHS Nancy Sullivan, BA Anjali Jain Research & Consulting Anjali Jain, MD Sigma Health Consulting Frances Murphy, MD, MPH Duty First Consulting Rachel Piccolino, BA Megan McGovern, BA MK Curley, BA *Additional contributor contact information is available in Appendix H in the full Dyslipidemia CPG. Methods The 2020 Dyslipidemia CPG is an update to the 2014 VA/DoD Dyslipidemia CPG. 